SCHEMBL4492465

SCHEMBL4492465

O=C(O)c1ccc2c(c1)ncn2-c1ccc(OCc2ccc(OC(F)(F)F)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 5/20 0.56
MRGPRX4 Q96LA9 1/20 0.55
THRB P10828 1/20 0.54
HPGD P15428 5/20 0.50
CYP19A1 P11511 1/20 0.49
CYP11B1 P15538 1/20 0.49
CYP11B2 P19099 1/20 0.49
GSK3B P49841 1/20 0.49
TSHR P16473 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RIPK1 Q13546 1/20 0.46
RIPK3 Q9Y572 1/20 0.46
TP53 P04637 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ALDH1A1 P00352 2/20 0.45
LMNA P02545 1/20 0.45
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
KMT2A Q03164 1/20 0.45
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4492204 0.91 FGFR1 (0.57) FGFR1MRGPRX4THRBHPGDGSK3B
SCHEMBL4501197 0.90 FGFR1 (0.60) FGFR1MRGPRX4HPGDCYP19A1CYP11B1
SCHEMBL1382311 0.86 MEN1 (0.55) HPGDCYP19A1CYP11B1CYP11B2GSK3B
SCHEMBL4502222 0.86 MAPT (0.65) THRBHPGDNPSR1TP53ALDH1A1
SCHEMBL2975358 0.85 MRGPRX4 (0.51) MRGPRX4HPGDCYP19A1CYP11B1CYP11B2
SCHEMBL1378432 0.84 KMT2A (0.58) HPGDCYP19A1CYP11B1CYP11B2RIPK1
SCHEMBL1379411 0.84 HPGD (0.63) FGFR1HPGDGSK3BRIPK1RIPK3
SCHEMBL1383456 0.83 MAPT (0.57) HPGDRIPK1RIPK3TP53ALDH1A1
SCHEMBL1382513 0.83 MEN1 (0.54) HPGDRIPK1RIPK3TP53TDP1
SCHEMBL1380123 0.83 KMT2A (0.63) HPGDRIPK1RIPK3TP53TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7521448-B2 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. 2006-08-24 US disclosed
EP-1664021-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-06-07 EP disclosed
WO-2005021531-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors KIT, CHUK, TNNI3K FGFR1 912/4885MRGPRX4 1285/4885THRB 3020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.